Intronix Technologies Blog
Myoguide recieves an FDA 510(k)
Myoguide receives a US FDA 510(k) K111985. We are preparing to complete the process for FDA clearance and will be launching an E-Commerce section from our website. The E-Commerce system will serve US and Canadian clinicians wishing to order Myoguide directly.
Back from Medica 2011
Intronix has been back from Medica for a week. Intronix is actively building our worldwide distribution network. We are very pleased to be in discussions with many very qualified candidates covering a number of different countries. Welcome to Myoguide
Intronix at MEDICA 2011
Intronix will be exhibiting for our third year at Medica. We will be pleased to meet with our friends and colleagues. We invite all interested distributors to contact us for an appointment to discuss possibilities. Its is a great opportunity to meet face to face and play with our products We are located in Hall…
Intronix Joins the International Association for the Study of Pain (IASP).
We are pleased to have joined the International Association for the Study of Pain (IASP).This is part of our commitment to keep abreast of issues concerning pain.We have also joined IASP forums on Muskuloskeletal Pain, Orofacial Pain, Pain and Movement, Neuropathic Pain, and Acute Pain.
Myoguide Animated Clinical Video
Our first Myoguide animated clinical demo is posted on the Intronix website. We are working on a series of these demos to illustrate how Myoguide integrates into the clinical setting. These new animations will complement the live clinical videos we have posted. The live videos are all about the procedures, and don’t really focus on…
New White Paper Introduced
We have just added an additional White Paper entitled: “Trigger Points”. This is a great addition to our first White Paper on “Needle EMG Guidance for Improved Outcomes”. This paper addresses the anatomical basis, symptoms, treatment modalities, with special attention to the role of botulinum toxin and needle EMG guided injection for “improved outcomes“. Simply…
Myoguide "White Papers" are introduced on Our Website
We have just launched a “White Papers” area on our website. There are hyperlinks on various pages to jump in. We started with “Needle EMG Guidance for Improved Outcomes”. There will be more to follow. Simply fill out the form with your information, and a copy will sent out promptly. Subscribe to our newsletter to…
Myoguide ™ Injection Site Targeting System Earns CE Mark
Myoguide poised to become essential pain and spasticity treatment tool in hands of European physicians We are extremely pleased to have obtained CE Mark approval for Myoguide. Clinicians throughout the European Union may now treat their patients suffering from acute and chronic pain, and spasticity with a highly portable electromyographic (EMG) precision device from Intronix…
European Pain Survey Yields Stunning Conclusions
“Chronic pain of moderate to severe intensity occurs in 19% of adult Europeans, seriously affecting the quality of their social and working lives. Very few were managed by pain specialists and nearly half received inadequate pain management. Although differences were observed between the 16 countries, we have documented that chronic pain is a major health…
A Conversation with Dr. Chan Gunn
I’d like to include an excerpt from an interchange with Dr. Chan Gunn. Of course, you should check out his website: www.istop.org . He’s a brilliant pain management physician. I must say that his work has influenced our direction early on in our research and development program. This excerpt leads to his assessment of Myoguide’s…